The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The impact of ESAs in lower-risk MDS
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, outlines the results of a study investigating the impact of erythropoietin stimulating agents (ESAs) in lower-risk myelodysplastic syndromes (MDS). The study showed that patients receiving ESAs prior to transfusions had an improved overall survival (OS), and that patients who were transfused had a worse quality of life (QoL) than patients who were not. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
